Literature DB >> 19292973

Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia.

Henry A Nasrallah1, Matcheri S Keshavan, Francine M Benes, David L Braff, Alan I Green, Raquel E Gur, John M Kane, Diana O Perkins, Peter J Weiden, Daniel R Weinberger, Christoph U Correll.   

Abstract

In mid-February 2008, a panel of 10 nationally recognized schizophrenia research experts was assembled in a Schizophrenia Summit to focus on controversies that exist in treating patients with schizophrenia. The current literature related to the diagnosis and etiopathology of schizophrenia was evaluated regarding the identification of a prodromal phase, brain changes, cognitive impairments, genetic factors, and use of neuroimaging in patients with schizophrenia. Further, consideration was given to evidence supporting the neuroprotective benefits of atypical antipsychotic medications, the benefits of treating patients during the prodromal period, the use of combination antipsychotic medications, the need to improve cognitive function, and the management of substance abuse. Summit faculty member opinion is compared with field survey results, and recommendations are made for future research. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292973

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

3.  A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study.

Authors:  Yange Li; Lei Zhang; Yan Zhang; Hui Wen; Jingjing Huang; Yifeng Shen; Huafang Li
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-19       Impact factor: 2.570

Review 4.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

5.  Iptakalim Preferentially Decreases Nicotine-induced Hyperlocomotion in Phencyclidine-sensitized Rats: A Potential Dual Action against Nicotine Addiction and Psychosis.

Authors:  Nick Volf; Gang Hu; Ming Li
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-12-20       Impact factor: 2.582

6.  Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia.

Authors:  Fu-Chun Zhou; Chuan-Yue Wang; Gabor S Ungvari; Chee H Ng; Yan Zhou; Liang Zhang; Jingjing Zhou; David H K Shum; David Man; Deng-Tang Liu; Jun Li; Yu-Tao Xiang
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.